Psychedelic drug MDMA eases PTSD symptoms in a study that paves the way for possible US approval

Federal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD. The advisers to the Food and Drug Administration are scheduled to vote on the drug's safety and effectiveness Tuesday, June 4, 2024, potentially setting the stage for federal approval later this year. (AP Photo/Robert F. Bukaty, File)

The psychedelic drug MDMA can reduce symptoms of post-traumatic stress disorder, researchers reported in a new study published Thursday.

The company sponsoring the research said it plans later this year to seek U.S. approval to market the drug, also known as ecstasy, as a PTSD treatment when combined with talk therapy.

“It’s the first innovation in PTSD treatment in more than two decades. And it’s significant because I think it will also open up other innovation,” said Amy Emerson, CEO of MAPS Public Benefit Corporation, the research sponsor.